These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12446422)

  • 21. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anemia with aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes].
    Passweg JR
    Ther Umsch; 2010 May; 67(5):251-5. PubMed ID: 20509122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
    Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
    Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.
    Wulfert M; Küpper AC; Tapprich C; Bottomley SS; Bowen D; Germing U; Haas R; Gattermann N
    Exp Hematol; 2008 May; 36(5):577-86. PubMed ID: 18439489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
    Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
    Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marrow failure.
    Bagby GC; Lipton JM; Sloand EM; Schiffer CA
    Hematology Am Soc Hematol Educ Program; 2004; ():318-36. PubMed ID: 15561690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractory anemia and the myelodysplastic syndromes.
    Lawrence LW
    Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
    Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM
    Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelodysplastic syndromes: what do hospitalists need to know?
    Zeidan AM; Faltas B; Douglas Smith B; Gore S
    J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
    Yoshimi A; Abdel-Wahab O
    Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Mechanisms in Myelodysplastic Syndrome.
    Glenthøj A; Ørskov AD; Hansen JW; Hadrup SR; O'Connell C; Grønbæk K
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27314337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ring sideroblasts and iron metabolism].
    Fujiwara T
    Rinsho Ketsueki; 2020; 61(7):770-778. PubMed ID: 32759564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?
    Visani G; Malagola M; Piccaluga PP; Isidori A
    Leuk Lymphoma; 2004 Aug; 45(8):1531-8. PubMed ID: 15370203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan.
    Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
    Leukemia; 1993 Apr; 7(4):499-508. PubMed ID: 8464227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic and prognostic values of in vitro culture growth patterns of marrow granulocyte-macrophage progenitors in patients with myelodysplastic syndrome.
    Shih LY; Chiu WF; Lee CT
    Leukemia; 1991 Dec; 5(12):1092-8. PubMed ID: 1774958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome.
    Sato T; Kim S; Selleri C; Young NS; Maciejewski JP
    Leukemia; 1998 Aug; 12(8):1187-94. PubMed ID: 9697872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunosuppressive therapy for myelodysplastic syndromes.
    Dobbelstein C; Ganser A
    Curr Pharm Des; 2012; 18(22):3184-9. PubMed ID: 22571697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment.
    Greenberg PL
    Leuk Res; 1998 Dec; 22(12):1123-36. PubMed ID: 9922076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.